McAndrews

About

  • The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.

« Senate Committee To Vote Wednesday on Bipartisan Follow-on Biologics Bill | Main | Federal Circuit Affirms Validity of Takeda's ACTOS Patent, Rejecting Alphapharm's Obviousness Arguments »

June 27, 2007

Follow-on Biologics Bill Approved by Senate Committee, Moves On to Full Senate

MarketWatch.com is reporting this afternoon that the Senate Committee on Health, Education, Labor and Pensions has voted in favor of the Biologics Price Competition and Innovation Act of 2007.  It is unclear whether the Committee amended the bill before voting on it.  The bill will now move to the Senate floor.

RELATED READING:

Posted by in Biosimilars |

Comments

The comments to this entry are closed.